Joseph G. Rogers, MD

The Texas Heart Institute's President and Chief Executive Officer, Joseph G. Rogers, MD, is a cardiologist and an Adjunct Professor in the Division of Cardiology at Duke University. He is an internationally recognized and widely published thought leader in heart failure, heart transplantation and mechanically assisted circulation. Show full bio

Dr. Rogers is passionate about value-based care initiatives, the delivery and implementation of care management and population health strategies. Dr. Rogers’ research focuses on clinical aspects of advanced heart failure, including pharmacologic and electrical treatments for systolic heart failure, the use of mechanical circulatory support devices, cardiac transplantation, and palliative care.

Before joining The Texas Heart Institute as President and CEO, he served as Chief Medical Officer at Duke University Health System (DUHS) in Durham, North Carolina, where he was responsible for providing clinical and strategic direction for physician activities across all of its clinical entities.

Dr. Rogers received his medical degree from the University of Nebraska College of Medicine in Omaha. He completed his residency training in internal medicine at the University of Nebraska and his fellowship in cardiology at Washington University in St. Louis, Missouri. He joined the faculty at Duke in 2004 and served in several leadership roles, including Associate Chief Medical Officer for strategic growth and implementation, interim chair of the school’s Department of Medicine, and member of the Board of Managers for Duke Connected Care, the health system’s Accountable Care Organization. He also served as a key strategic health system liaison to the Private Diagnostic Clinic, the physician practice organization for Duke providers, where he championed innovations in safety and quality across the health system.

Joseph G. Rogers, MD
Director, The Texas Heart Institute at Baylor College of Medicine
O’Quinn/Willerson Endowed Chair
The Texas Heart Institute
6770 Bertner Avenue, MC 3-116
Houston, TX 77030
Office: 832-355-9320 | Fax: 832-355-6810
Email: jrogers@texasheart.org

See Publications

Interests

  • Advanced heart failure
  • Investigative pharmacologic and electrical treatments for systolic heart failure
  • Mechanical circulatory support devices
  • Cardiac transplantation
  • Palliative care in the treatment of heart failure

Education

  • Medical School:

    University of Nebraska (Omaha)

  • Residency:

    University of Nebraska (Omaha)

  • Fellowships:

    Cardiovascular Disease Fellowship, Washington University (St. Louis, Missouri)

Publications

Raghuram, A., Sprung, K., Coulter, S. et al. (2025). Shaping the Future of “Cardio-Kidney-Metabolic” Health: Insights From The Texas Heart Institute’s 2024 Cardiometabolic Syndrome Conference. Texas Heart Institute Journal 52, e248536. https://doi.org/10.14503/THIJ-24-8536.
Hussain, A., Ramsey, D., Lee, M. et al. (2023). Utilization rates of SGLT2 inhibitors among patients with type 2 diabetes, heart failure, and atherosclerotic cardiovascular disease: Insights from the Department of Veterans Affairs. JACC Heart Fail, S2213-1779(23)00185–3. https://doi.org/10.1016/j.jchf.2023.03.024.
Maitra, N. S., Dugger, S. J., Balachandran, I. C. et al. (2023). Impact of the 2018 UNOS heart transplant policy changes on patient outcomes. JACC Heart Fail, S2213-1779(23)00038–0. https://doi.org/10.1016/j.jchf.2023.01.009.
Civitello, A. B. and Rogers, J. G. (2023). Toward a self-actuating continuous flow ventricular assist device: the pudding is in the proof. ASAIO J 69, 59–60. https://doi.org/10.1097/MAT.0000000000001881.
Wang, N., Gray, Z., Rogers, J. G. et al. (2023). Robot-assisted resection of tricuspid valve papillary fibroelastoma. Annals of Thoracic Surgery Short Reports, S2772993123001791. https://doi.org/10.1016/j.atssr.2023.04.007.
Felker, G. M., Buttrick, P., Rosenzweig, A. et al. (2022). Heart Failure Strategically Focused Research Network: Summary of results and future directions. J Am Heart Assoc 11, e025517. https://doi.org/10.1161/JAHA.122.025517.
Golden, L. and Rogers, J. G. (2022). Heart failure drug therapy: New treatments, new guidelines. Tex Heart Inst J 49, e227920. https://doi.org/10.14503/THIJ-22-7920.
Cogswell, R. and Rogers, J. G. (2022). Residual heart failure on mechanically assisted circulation: A call to action. JACC Heart Fail 10, 482–484. https://doi.org/10.1016/j.jchf.2022.05.002.
Al Rifai, M., Newby, L. K., Nair, A. P. et al. (2022). SGLT-2 inhibitors for patients with heart failure: what have we learned recently? Curr Atheroscler Rep. https://doi.org/10.1007/s11883-022-01038-2.
Shah, P. and Rogers, J. G. (2022). Thrivival: Thriving and surviving for left ventricular assist device patients. JACC Heart Fail 10, 333–335. https://doi.org/10.1016/j.jchf.2022.02.009.

Recent News

wearable technology

Shaping the Future of Metabolic Health: Insights from The Texas Heart Institute

On August 23, 2024, The Texas Heart Institute hosted the Cardiometabolic Syndrome Conference: A Population Health Crisis, bringing together leading...

Heart Month 2025

February has arrived, marking the celebration of American Heart Month. This is an excellent opportunity for the nation to unite...

Advancing Cardiovascular Research: The New Cath Lab at The Texas Heart Institute

Innovation drives every breakthrough at The Texas Heart Institute (THI), and we are excited to announce the launch of our...